Consistent with our hypothesis, blocking TGF-β signaling with a TGF-β receptor inhibitor abolished the platelet releasate-induced proliferation of HCC cells and down-regulated KLF6 expression. The gene discussed is KLF6; the disease is hepatocellular carcinoma.